acquisition of MiroBio for $405 million. In February 2023, the business, through Kite Pharma completed its acquisition of Tmunity Therapeutics Acquisition history Gilead Sciences NeXstar Pharmaceuticals (Acq 1999) Triangle Pharmaceuticals (Acq 2003) Myogen, Inc. (Acq 2006) Corus Pharma, Inc (Acq 2006) Raylo Chemicals (Acq 2006) CV Therapeutics, Inc. (Acq 2009) CGI Pharmaceuticals (Acq 2010) Calistoga Pharmaceuticals (Acq 2011) Pharmasset Inc (Acq 2011) Phenex Pharmaceuticals (Acq 2015) EpiTherapeutics (Acq 2015) Galapagos NV (Acq 2015) Nimbus Apollo, Inc. (Acq 2016) Kite Pharma (Acq 2017) Cell Design Labs (Acq 2017) Tmunity Therapeutics (Acq 2023) Forty Seven (Acq 2020) Immunomedics (Acq 2020) MYR GmbH (Acq 2020) MiroBio (Acq 2022) Treatments for hepatitis C The drug sofosbuvir had been part of the 2011 acquisition of Pharmasset. In 2013, the FDA approved this drug, under the trade name Sovaldi, as a treatment for the hepatitis C virus. Forbes magazine ranked Gilead its number 4 drug company, citing a market capitalization of US$113 billion and stock appreciation of 100%, and describing their 2011 purchase of Pharmasset for $11 billion as "one of the best pharma acquisitions ever". Deutsche Bank estimated Sovaldi sales in the year's final quarter would be $53 million, and Barron's noted the FDA approval and subsequent strong sales of the "potentially revolutionary" drug as a positive indicator for the stock. On July 11, 2014, the United States Senate Committee on Finance investigated Sovaldi's high price ($1,000 per pill; $84,000 for the full 12-week regimen). Senators questioned the extent to which the market was operating "efficiently and rationally", and committee chairman Ron Wyden (D-Oregon) and ranking minority member Chuck Grassley (R-Iowa) wrote to CEO John C. Martin asking Gilead to justify the price for this drug. The committee hearings did not result in new law, but in 2014 and 2015, due to negotiated and mandated discounts, Sovaldi was sold well below the list price. For poorer countries, Gilead licensed multiple companies to produce generic versions of Sovaldi; in India, a pill's price was as low as $4.29. Gilead later combined Sovaldi with other antivirals in single-pill combinations. First, Sovaldi was combined with ledipasvir and marketed as Harvoni. This treatment for hepatitis C cures the patient in 94% to 99% of cases (HCV genotype 1). By 2017, Gilead was reporting drastic drops in Sovaldi revenue from year to year, not only because of pricing pressure but because the number of suitable patients decreased. Later single-pill combinations